Adicet Bio, Inc. (ACET)

Market Cap	81.56M
Revenue (ttm)	n/a
Net Income (ttm)	-115.01M
Shares Out	10.11M
EPS (ttm)	-20.18
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	248,267
Open	8.13
Previous Close	7.90
Day's Range	7.76 - 8.55
52-Week Range	7.15 - 17.44
Beta	1.61
Analysts	Strong Buy
Price Target	65.33 (+709.54%)
Earnings Date	Mar 5, 2026

About ACET

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company’s lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodg...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1947
• Employees: 152
• Stock Exchange: NASDAQ
• Ticker Symbol: ACET
• Website: https://www.adicetbio.com

Analyst Summary

According to 5 analysts, the average rating for ACET stock is "Strong Buy." The 12-month stock price target is $65.33, which is an increase of 709.54% from the latest price.

Price Target

$65.33

(709.54% upside)

Analyst Consensus: Strong Buy